Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
09 April 2019Website:
http://telomirpharma.comNext earnings report:
29 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 23:13:09 GMTDividend
Analysts recommendations
Institutional Ownership
TELO Latest News
MIAMI, FL / ACCESSWIRE / November 21, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced groundbreaking preclinical results confirming the efficacy of Telomir-1, a compound designed to effectively turn back the biological clock and support longevity. Using advanced in vivo microfluidic technology, in collaboration with Nagi Biosciences SA, the study demonstrates significant age-reversal effects in aging model organisms treated with Telomir-1, effectively turning back the biological clock.
Toronto, Ontario--(Newsfile Corp. - September 10, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that it is evaluating its minimal residual disease (MRD) biomarker assay technologies in multiple myeloma (MM) patients as a part of the TELO-DMRD clinical validation study. Telo's MRD assays are being evaluated utilizing Adaptive Biotechnologies' clonoSEQ assay technology as a component of Telo's ongoing MRD clinical trial, TELO-DMRD (NCT05530096), being conducted with McGill University, Montreal, Canada.
Commences the study, The Safety of Telomir-1 when Administered Orally to Geriatric Laboratory Beagle Dogs for 63 Consecutive Days study to evaluate the safety of Telomir-1 on geriatric canines
Telomir Pharmaceuticals plans to raise $7 million through an IPO to fund its development of treatments for age-related inflammatory conditions. The company's lead candidate, TELOMIR-1, has the potential to act as an Interleukin-17 inhibitor for conditions such as hemochromatosis and osteoarthritis. Given TELO's thin capitalization, high valuation expectations and early stage of development, my opinion on the IPO is to Sell [Avoid].
What type of business is Telomir Pharmaceuticals Common Stock?
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
What sector is Telomir Pharmaceuticals Common Stock in?
Telomir Pharmaceuticals Common Stock is in the Healthcare sector
What industry is Telomir Pharmaceuticals Common Stock in?
Telomir Pharmaceuticals Common Stock is in the Biotechnology industry
What country is Telomir Pharmaceuticals Common Stock from?
Telomir Pharmaceuticals Common Stock is headquartered in United States
When did Telomir Pharmaceuticals Common Stock go public?
Telomir Pharmaceuticals Common Stock initial public offering (IPO) was on 09 April 2019
What is Telomir Pharmaceuticals Common Stock website?
https://telomirpharma.com
Is Telomir Pharmaceuticals Common Stock in the S&P 500?
No, Telomir Pharmaceuticals Common Stock is not included in the S&P 500 index
Is Telomir Pharmaceuticals Common Stock in the NASDAQ 100?
No, Telomir Pharmaceuticals Common Stock is not included in the NASDAQ 100 index
Is Telomir Pharmaceuticals Common Stock in the Dow Jones?
No, Telomir Pharmaceuticals Common Stock is not included in the Dow Jones index
When was Telomir Pharmaceuticals Common Stock the previous earnings report?
No data
When does Telomir Pharmaceuticals Common Stock earnings report?
The next expected earnings date for Telomir Pharmaceuticals Common Stock is 29 November 2024